MDA-MB-468 Xenograft Model Service for Breast Cancer

The MDA-MB-468 xenograft model delivers a highly robust in vivo translational platform specifically optimized for evaluating candidate therapies targeting EGFR-overexpressing, PTEN-deficient basal-like triple-negative breast cancers (TNBC). Alfa Cytology provides a comprehensive, end-to-end MDA-MB-468 xenograft model service, integrating fully authenticated cellular assets with standardized procedural protocols to accelerate preclinical oncology drug discovery timelines.

Overview of MDA-MB-468 Xenograft Model for Breast Cancer

The MDA-MB-468 cell line is a widely utilized and exceptionally well-characterized human mammary carcinoma model in preclinical oncology, serving as a classic representative of the Basal-like molecular subtype of TNBC. Originally isolated from the pleural effusion of a patient with metastatic breast adenocarcinoma, this model is phenotypically defined by the absolute absence of ER, PR, and HER2 expression. Crucially, MDA-MB-436 or other claudin-low lines present mesenchymal traits, whereas MDA-MB-468 preserves distinct epithelial characteristics alongside prominent genomic hallmarks, including a massive amplification of the EGFR gene and a homozygous deletion of the PTEN tumor suppressor gene. This PTEN loss drives constitutive hyperactivation of the downstream PI3K/AKT/mTOR signaling cascade, making the MDA-MB-468 model a vital test matrix for validating novel EGFR inhibitors, anti-EGFR ADCs, AKT/mTOR antagonists, and therapeutic strategies targeting cell cycle dysregulation due to its concurrent Rb pathway loss.

When established in vivo as a xenograft in immunocompromised mice, MDA-MB-468 cells form poorly differentiated, highly proliferative solid tumors that closely mirror the aggressive clinical progression, extensive necrosis, and therapeutic resistance profiles observed in clinical basal-like TNBC patients.

Cell Line Information: MDA-MB-468

The MDA-MB-468 cell line maintains a distinct epithelial-like morphology in vitro and reliably preserves its signature EGFR amplification, PTEN deletion, and triple-negative status upon in vivo transplantation.

Our Services

Alfa Cytology provides a fully integrated, turnkey solution for the MDA-MB-468 Xenograft Model Service. Our dedication to quality begins with rigorous cell line authentication and mycoplasma testing. We manage every critical step of the preclinical journey—from standardized cell preparation, orthotopic or subcutaneous inoculation, in-life monitoring, to comprehensive endpoint analyses including IHC for EGFR and PTEN status and PK/PD profiling. Leveraging our expertise in EGFR-amplified, PTEN-deficient basal-like TNBC models, we deliver robust data packages tailored to accelerate your drug discovery programs.

Workflow of MDA-MB-468 Xenograft Model Construction

Alfa Cytology executes a standardized and strictly regulated workflow to build and validate the MDA-MB-468 xenograft model:

• Cell Culture & Quality Control: MDA-MB-468 cells are cultivated in cell-bank-certified growth media under optimized parameters. Quality control verification involves mandatory STR profiling and mycoplasma clearance checks to guarantee phenotypic identity and purity before inoculation.
• Host Selection & Acclimatization: Standardized immunocompromised mice are selected based on specific study requirements and acclimated to controlled facility parameters to ensure baseline physiological stability.
• Precision Inoculation: A calibrated suspension of high-viability MDA-MB-468 cells is prepared and blended with a verified biological matrix carrier to optimize spatial distribution and support initial engraftment. The mixture is precisely injected in vivo via subcutaneous or orthotopic routes.
• Longitudinal Growth Tracking: Following model establishment, tumor growth is tracked systematically using high-precision digital calipers under continuous health monitoring. Animal weights and general welfare behavior are routinely recorded to establish dependable growth kinetics.
• Stratification & Dosing: Once the tumors reach a predetermined, statistically optimal volume range, animals are randomized into therapeutic cohorts to balance group parameters perfectly before dosing protocols begin.

Fig 1. MDA-MB-468 Xenograft Model Construction Workflow

Case Study - MDA-MB-468 Xenograft Model Development

In a recent preclinical trial conducted at Alfa Cytology, the MDA-MB-468 xenograft model was successfully utilized to evaluate the efficacy of a novel small-molecule inhibitor targeting hyperactivated downstream AKT signaling in PTEN-deficient triple-negative breast cancer. Under optimized modeling conditions and standardized inoculation protocols, our technical team achieved highly reproducible tumor engraftment and exceptionally uniform growth curves across all experimental arms, allowing for an unobstructed and definitive assessment of therapeutic efficacy.

Our Advantages

Choosing the right partner for your aggressive, EGFR-amplified, basal-like triple-negative breast cancer research is critical for generating high-quality, reproducible data. Alfa Cytology stands out by offering specialized expertise and high-standard preclinical services:

• Model Authenticity: Fully verified human tumor cell lines with stable, traceable genetic hallmarks.
• Technical Consistency: Optimized inoculation protocols ensuring uniform tumor growth and minimizing variance.
• Multi-Parametric Endpoints: Capacity for advanced readouts, including digital tumor kinetics, target receptor expression analysis, and PK/PD tissue processing.
• Regulatory Compliance: Studies executed by a specialized team adhering strictly to international preclinical research standards.

Contact Us

Are you looking to advance your therapeutic pipeline against aggressive, EGFR-amplified, basal-like triple-negative breast cancer using the robust MDA-MB-468 xenograft platform? The expert scientific team at Alfa Cytology is ready to build a customized study design that fulfills your strategic research goals. Please contact us today to speak directly with an oncology specialist and request a project-specific consultation and quotation.

For research use only. Not intended for any clinical use.